Hennion & Walsh Asset Management Inc. Has $695,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Hennion & Walsh Asset Management Inc. increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 89.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,315 shares of the company’s stock after purchasing an additional 7,235 shares during the period. […]
More Stories
Radius Recycling (NASDAQ:RDUS) Issues Quarterly Earnings Results
Radius Recycling (NASDAQ:RDUS – Get Free Report) released its earnings results on Tuesday. The basic materials company reported ($1.33) earnings...
RPM International (NYSE:RPM) Releases Earnings Results, Beats Expectations By $0.05 EPS
RPM International (NYSE:RPM – Get Free Report) announced its quarterly earnings results on Tuesday. The specialty chemicals company reported $1.39...
StockNews.com Initiates Coverage on Cumulus Media (NASDAQ:CMLS)
StockNews.com began coverage on shares of Cumulus Media (NASDAQ:CMLS – Free Report) in a research report report published on Wednesday....
Insider Selling: SentinelOne, Inc. (NYSE:S) CEO Sells 60,864 Shares of Stock
SentinelOne, Inc. (NYSE:S – Get Free Report) CEO Tomer Weingarten sold 60,864 shares of the stock in a transaction that...
BlackRock (NYSE:BLK) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on shares of BlackRock (NYSE:BLK – Free Report) in a research report report published on Wednesday morning....
Summit Materials (NYSE:SUM) Downgraded to Hold Rating by Stephens
Summit Materials (NYSE:SUM – Get Free Report) was downgraded by analysts at Stephens from a “strong-buy” rating to a “hold”...